Intervention Studies of Inhaled Corticosteroids Combined with Long-acting Theophylline or Long-acting β2-agonists in Patients with Moderate to Severe Asthma: A Randomized, Controlled Study

被引:3
作者
Wang, Yan [1 ]
Chen, Ping [2 ]
Dai, Anna [1 ]
Shang, Shengyun [1 ]
Kong, Lingfei [1 ]
机构
[1] China Med Univ, Hosp 1, Inst Resp Dis, 155 Nanjing North St, Shenyang 110001, Liaoning Provin, Peoples R China
[2] Gen Hosp Shenyang Mil Reg, Resp Med, Shenyang, Liaoning, Peoples R China
关键词
fluticasone aerosol; moderate to severe persistent asthma; salmeterol/fluticasone propionate aerosol; theophylline tablets; treatment; PERSISTENT ASTHMA; LUNG-FUNCTION; BUDESONIDE; THERAPY; MONTELUKAST;
D O I
10.1016/j.clinthera.2016.10.015
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Purpose: To evaluate and contrast the therapeutic effect and safety of fluticasone aerosol combined with theophylline tablets in patients with moderate to severe asthma, compared with salmeterol/fluticasone propionate aerosol. Methods: After a screening period, patients meeting the inclusion criteria were randomly assigned to the experiment group (fluticasone aerosol combined with theophylline tablets) or the control group (salmeterol/ fluticasone aerosol combined with placebo tablets) for 12 weeks of treatment. The main outcome measurements were forced expiratory volume in 1 second and fractional concentration of exhaled nitric oxide value, whereas the secondary measures were forced vital capacity, peak expiratory flow value, and Asthma Control Test/Asthma Quality of Life Questionnaire score. Findings: Forty-four cases completed the course, with 23 cases in the experiment group and 21 cases in the control group. The forced expiratory volume in 1 second values of both groups were significantly improved from before (P < 0.05). The fractional concentration of exhaled nitric oxide values of both groups were significantly decreased from before (P < 0.05). The secondary outcome measurements after treatment achieved obvious improvement from baseline (P < 0.05) in both. There was no significant difference between the 2 groups in all measurements. In addition, the blood biochemistry results, ECG results, and vital signs of both groups had no significant abnormality. Implications: There was no significant difference in therapeutic effect and safety between the 2 groups in treating patients with moderate to severe persistent asthma, which suggests that fluticasone aerosol combined with theophylline tablets is worth considering for use in primary hospitals or for low-income populations. (C) 2016 Elsevier HS Journals, Inc. All rights reserved.
引用
收藏
页码:2622 / 2627
页数:6
相关论文
共 50 条
  • [21] Addition of long-acting beta2-agonists to inhaled corticosteroids for chronic asthma in children
    Chauhan, Bhupendrasinh F.
    Chartrand, Caroline
    Chroinin, Muireann Ni
    Milan, Stephen J.
    Ducharme, Francine M.
    COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2015, (11):
  • [22] Inhaled corticosteroids with combination inhaled long-acting beta2-agonists and long-acting muscarinic antagonists for chronic obstructive pulmonary disease
    van Geffen, Wouter H.
    Tan, Daniel J.
    Walters, Julia A. E.
    Walters, E. Haydn
    COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2023, (12):
  • [23] Inhaled corticosteroids with combination inhaled long-acting beta2-agonists and long-acting muscarinic antagonists for chronic obstructive pulmonary disease
    Tan, Daniel J.
    White, Clinton J.
    Walters, Julia A. E.
    Walters, E. Haydn
    COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2016, (11):
  • [24] Addition of long-acting beta-agonists to inhaled corticosteroids for chronic asthma in children
    Ni, Chroinin M.
    Lasserson, T. J.
    Greenstone, I
    Ducharme, F. M.
    COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2009, (03):
  • [25] Long-acting Beta-Agonists with and without Inhaled Corticosteroids and Catastrophic Asthma Events
    Salpeter, Shelley R.
    Wall, Andrew J.
    Buckley, Nicholas S.
    AMERICAN JOURNAL OF MEDICINE, 2010, 123 (04) : 322 - U3
  • [26] Therapeutic preferences and factors determining the use of inhaled corticosteroids with long-acting β2-agonists in patients with asthma and chronic obstructive pulmonary disease
    Olszanecka-Glinianowicz, Magdalena
    Chudek, Jerzy
    Almgren-Rachtan, Agnieszka
    POSTEPY DERMATOLOGII I ALERGOLOGII, 2021, 38 (05): : 752 - 760
  • [27] Safety in the use of long-acting β2 agonists in asthma
    Solnor, Ludvik Saxhaug
    Skeie, Oystein Stenerud
    Spigset, Olav
    Slordal, Lars
    TIDSSKRIFT FOR DEN NORSKE LAEGEFORENING, 2019, 139 (17) : 1666 - 1670
  • [28] Adding tiotropium or long-acting β2-agonists to inhaled corticosteroids: Asthma-related exacerbation risk and healthcare resource utilization
    Hanania, Nicola A.
    Settipane, Russell A.
    Khoury, Samir
    Shaikh, Asif
    Dotiwala, Zenobia
    Casciano, Julian
    Foggs, Michael B.
    ALLERGY AND ASTHMA PROCEEDINGS, 2023, 44 (06) : 413 - 421
  • [29] Long-Acting β- Agonist Treatment in Patients with Persistent Asthma Already Receiving Inhaled Corticosteroids
    Robert J. Hancox
    D. Robin Taylor
    BioDrugs, 2001, 15 : 11 - 24
  • [30] Stopping long-acting beta2-agonists (LABA) for adults with asthma well controlled by LABA and inhaled corticosteroids
    Ahmad, Shaleen
    Kew, Kayleigh M.
    Normansell, Rebecca
    COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2015, (06):